Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure

David Jassir, Onur Odabasi, Orlando W Gomez-Marin, Craig A. Buchman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

OBJECTIVE: We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies. STUDY DESIGN AND SETTING: Bilateral myringotomies were performed using the argon laser in 40 guinea pigs with normal ears. Pledgets with (0.05, 0.2, 0.4, or 2.0 mg/mL) mitomycin C were applied topically. Monitoring consisted of weekly or bi-weekly otomicroscopy. RESULTS: As in previous studies, all saline-treated myringotomies closed by day 7. By day 14, all myringotomies (100%) in the 0.05 mg/mL group were closed. By contrast, all myringotomies (100%) remained patent in the 0.2 and 0.4 mg/mL treatment groups, and 56% of the myringotomies remained patent in the 2.0 mg/mL group at day 14. By day 56, all myringotomies were closed in the 2.0 mg/mL group, 5 (50%) myringotomies were patent in the 0.4 mg/mL group, and 1 (11%) myringotomy was patent in the 0.2 mg/mL group. The study was terminated on day 84 (12 weeks). At that time, only the 0.4 mg/mL group had patent myringotomies (n = 3; 30%). The highest dose (2.0 mg/mL) of mitomycin was significantly associated with otorrhea. Otorrhea also appeared to be associated with earlier myringotomy closure. CONCLUSION: There is a dose-response curve for topical mitomycin C when used for prolonging myringotomy patency in doses up to 0.4 mg/mL. Higher doses do not appear to prolong patency and are associated with greater otorrhea, suggesting middle ear toxicity.

Original languageEnglish
Pages (from-to)471-474
Number of pages4
JournalOtolaryngology - Head and Neck Surgery
Volume129
Issue number5
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Mitomycin
Lasers
Argon
Middle Ear
Ear
Guinea Pigs

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure. / Jassir, David; Odabasi, Onur; Gomez-Marin, Orlando W; Buchman, Craig A.

In: Otolaryngology - Head and Neck Surgery, Vol. 129, No. 5, 01.11.2003, p. 471-474.

Research output: Contribution to journalArticle

Jassir, David ; Odabasi, Onur ; Gomez-Marin, Orlando W ; Buchman, Craig A. / Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure. In: Otolaryngology - Head and Neck Surgery. 2003 ; Vol. 129, No. 5. pp. 471-474.
@article{fe23d54865724c5daa11038fc8a135f1,
title = "Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure",
abstract = "OBJECTIVE: We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies. STUDY DESIGN AND SETTING: Bilateral myringotomies were performed using the argon laser in 40 guinea pigs with normal ears. Pledgets with (0.05, 0.2, 0.4, or 2.0 mg/mL) mitomycin C were applied topically. Monitoring consisted of weekly or bi-weekly otomicroscopy. RESULTS: As in previous studies, all saline-treated myringotomies closed by day 7. By day 14, all myringotomies (100{\%}) in the 0.05 mg/mL group were closed. By contrast, all myringotomies (100{\%}) remained patent in the 0.2 and 0.4 mg/mL treatment groups, and 56{\%} of the myringotomies remained patent in the 2.0 mg/mL group at day 14. By day 56, all myringotomies were closed in the 2.0 mg/mL group, 5 (50{\%}) myringotomies were patent in the 0.4 mg/mL group, and 1 (11{\%}) myringotomy was patent in the 0.2 mg/mL group. The study was terminated on day 84 (12 weeks). At that time, only the 0.4 mg/mL group had patent myringotomies (n = 3; 30{\%}). The highest dose (2.0 mg/mL) of mitomycin was significantly associated with otorrhea. Otorrhea also appeared to be associated with earlier myringotomy closure. CONCLUSION: There is a dose-response curve for topical mitomycin C when used for prolonging myringotomy patency in doses up to 0.4 mg/mL. Higher doses do not appear to prolong patency and are associated with greater otorrhea, suggesting middle ear toxicity.",
author = "David Jassir and Onur Odabasi and Gomez-Marin, {Orlando W} and Buchman, {Craig A.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1016/S0194-5998(03)01394-9",
language = "English",
volume = "129",
pages = "471--474",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure

AU - Jassir, David

AU - Odabasi, Onur

AU - Gomez-Marin, Orlando W

AU - Buchman, Craig A.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - OBJECTIVE: We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies. STUDY DESIGN AND SETTING: Bilateral myringotomies were performed using the argon laser in 40 guinea pigs with normal ears. Pledgets with (0.05, 0.2, 0.4, or 2.0 mg/mL) mitomycin C were applied topically. Monitoring consisted of weekly or bi-weekly otomicroscopy. RESULTS: As in previous studies, all saline-treated myringotomies closed by day 7. By day 14, all myringotomies (100%) in the 0.05 mg/mL group were closed. By contrast, all myringotomies (100%) remained patent in the 0.2 and 0.4 mg/mL treatment groups, and 56% of the myringotomies remained patent in the 2.0 mg/mL group at day 14. By day 56, all myringotomies were closed in the 2.0 mg/mL group, 5 (50%) myringotomies were patent in the 0.4 mg/mL group, and 1 (11%) myringotomy was patent in the 0.2 mg/mL group. The study was terminated on day 84 (12 weeks). At that time, only the 0.4 mg/mL group had patent myringotomies (n = 3; 30%). The highest dose (2.0 mg/mL) of mitomycin was significantly associated with otorrhea. Otorrhea also appeared to be associated with earlier myringotomy closure. CONCLUSION: There is a dose-response curve for topical mitomycin C when used for prolonging myringotomy patency in doses up to 0.4 mg/mL. Higher doses do not appear to prolong patency and are associated with greater otorrhea, suggesting middle ear toxicity.

AB - OBJECTIVE: We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies. STUDY DESIGN AND SETTING: Bilateral myringotomies were performed using the argon laser in 40 guinea pigs with normal ears. Pledgets with (0.05, 0.2, 0.4, or 2.0 mg/mL) mitomycin C were applied topically. Monitoring consisted of weekly or bi-weekly otomicroscopy. RESULTS: As in previous studies, all saline-treated myringotomies closed by day 7. By day 14, all myringotomies (100%) in the 0.05 mg/mL group were closed. By contrast, all myringotomies (100%) remained patent in the 0.2 and 0.4 mg/mL treatment groups, and 56% of the myringotomies remained patent in the 2.0 mg/mL group at day 14. By day 56, all myringotomies were closed in the 2.0 mg/mL group, 5 (50%) myringotomies were patent in the 0.4 mg/mL group, and 1 (11%) myringotomy was patent in the 0.2 mg/mL group. The study was terminated on day 84 (12 weeks). At that time, only the 0.4 mg/mL group had patent myringotomies (n = 3; 30%). The highest dose (2.0 mg/mL) of mitomycin was significantly associated with otorrhea. Otorrhea also appeared to be associated with earlier myringotomy closure. CONCLUSION: There is a dose-response curve for topical mitomycin C when used for prolonging myringotomy patency in doses up to 0.4 mg/mL. Higher doses do not appear to prolong patency and are associated with greater otorrhea, suggesting middle ear toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0242494404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242494404&partnerID=8YFLogxK

U2 - 10.1016/S0194-5998(03)01394-9

DO - 10.1016/S0194-5998(03)01394-9

M3 - Article

C2 - 14595268

AN - SCOPUS:0242494404

VL - 129

SP - 471

EP - 474

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 5

ER -